miR24-2 promotes malignant progression of human liver cancer stem cells by enhancing tyrosine kinase Src epigenetically

Abstract miR24-2 is associated with human tumorigenesis, however, its molecular mechanisms are poorly understood. Herein, our findings demonstrate that miR24-2 promotes the proliferation ability in vitro and the tumorigenic ability in vivo in human liver cancer stem cells. Mechanically, the miR24-2 targets for 3'-UTR (2627-2648) of protein arginine methyltransferase 7 inhibits the translational ability of prmt7 gene. Moreover, miR24-2 inhibits the di-/tri-methylation of histone H4 arginine 3 by reducing PRMT7, and then promotes the expression of Nanog via long noncoding RNA HULC. Notably, miR24-2 inhibits histone deacetylase HDAC3 through miR675 which promotes the acetylation of histone H4 at lysine 16. Subsequently, miR24-2 enhances the interaction between LC3 and ATG4 dependent on PI3K and triggers cellular autophagy. Strikingly, miR24-2 inhibits the degradation of pyruvate kinase M1 via autophagosome-P62 in human liver cancer stem cells. Furthermore, miR-24-2 enhances the activity of Src by promoting the binding of PKM1 to the Src promoter regions in human liver cancer stem cells. In particular, our results also indicate that src gene determines the oncogenic fuctions of miR24-2. These results provided a valuable theoretical basis for the discovery of liver cancer therapeutic targets and diagnosis markers based on miR24-2.